GlassScriptPhysician profile
Jack J Devita
NPI 1588624340
$9,566.62
in general payments reported to CMS, 2019-2025
27 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $682 · 2021: $1,518 · 2022: $1,426 · 2023: $1,709 · 2024: $1,572 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,875.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,426.35 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,777.05 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $725.81 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $645.54 | 2019-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $486.63 | 2022-2025 | Dupixent |
| Pfizer INC. | $396.74 | 2023-2025 | |
| Gilead Sciences, INC. | $335.46 | 2020-2025 | Epclusa |
| Ardelyx, INC. | $274.65 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $193.86 | 2025 | Voquezna |
| Genzyme Corporation | $158.73 | 2022-2025 | |
| Lilly USA, LLC | $154.45 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $151.98 | 2019-2024 | Linzess |
| Qol Medical, LLC | $147.59 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $144.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals LP | $96.81 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $88.10 | 2021-2024 | Zeposia |
| Medtronic, INC. | $85.37 | 2022 | |
| Braintree Laboratories, INC. | $55.91 | 2021-2025 | Sutab, Suflave |
| Daiichi Sankyo INC. | $39.61 | 2019-2022 | |
| Celltrion USA INC. | $34.74 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $29.04 | 2021 | |
| Intercept Pharmaceuticals, INC. | $27.34 | 2020-2024 | |
| Novo Nordisk INC | $26.45 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $25.31 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $15.00 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $12.27 | 2020 | |
| Digestive Care, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Devita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.